- RESEARCH USE ONLY
- INDEPENDENTLY THIRD-PARTY TESTED
- COA EVERY LOT
- US-BASED OPERATIONS
| Specification | Details |
|---|---|
| Compound | CJC-1295 (DAC) |
| Type | Synthetic GHRH analogue |
| Parent Sequence | GHRH(1-29) analogue |
| Molecular Formula | C₁₆₅H₂₆₉N₄₇O₄₆ |
| Molecular Weight | 3647.2 g/mol |
| CAS | 446262-90-4 |
| Quantity | 2 mg |
| Purity | ≥99% HPLC Certified |
| Form | Lyophilized powder |
| Appearance | White to off-white powder |
| Solubility | Soluble in laboratory-grade sterile water |
| Documentation | Certificate of Analysis included in product documentation |
$49.99
For Research Use Only | Not for Human or Veterinary Use
CJC-1295 (DAC) is a synthetic analogue of human growth hormone-releasing hormone (GHRH) designed from the GHRH(1-29) sequence. The molecule incorporates a reactive maleimide-containing modification that allows it to bind covalently to circulating albumin. This design distinguishes CJC-1295 (DAC) from shorter-acting GHRH analogues without the Drug Affinity Complex (DAC) modification.
The albumin-binding property of the DAC modification has been investigated as a mechanism for increasing molecular persistence in circulation. Experimental research has examined CJC-1295 in receptor signaling, pharmacokinetics, and growth-hormone-related endocrine models.
The molecular formula, molecular weight, and CAS information are based on the CJC-1295 chemical record maintained by PubChem.
CJC-1295 was developed from human GHRH(1-29), the N-terminal portion of human growth hormone-releasing hormone that retains activity at the GHRH receptor. The DAC version incorporates a maleimido-containing modification at the peptide's C-terminal region.
The defining feature of CJC-1295 (DAC) is its ability to react with albumin through the maleimide group. Research demonstrated that CJC-1295 can form a covalent association with circulating serum albumin, producing a substantially longer-lasting circulating peptide species than unmodified GHRH(1-29).
This albumin-binding mechanism is the basis for the Drug Affinity Complex (DAC) designation. Rather than relying solely on the intrinsic stability of the GHRH peptide, the modification changes its pharmacokinetic behavior through association with a large circulating protein.
CJC-1295 has been investigated as an agonist of the GHRH receptor, a receptor expressed primarily in the anterior pituitary. Experimental work demonstrated that CJC-1295 retained activity in cultured rat anterior pituitary cells and produced measurable growth-hormone secretion in animal studies.
This makes CJC-1295 useful as an experimental analogue for studying the relationship between GHRH receptor activation and downstream growth-hormone signaling.
Human pharmacokinetic research has examined CJC-1295 in healthy adult subjects. In one randomized, placebo-controlled study, the estimated plasma half-life following administration was approximately 5.8–8.1 days, demonstrating substantially longer persistence than native GHRH.
The same study observed sustained changes in circulating GH and IGF-I concentrations following experimental administration. These findings describe the pharmacology observed under the specific conditions of that clinical research and should not be interpreted as claims about the research material supplied on this page.
The DAC modification is an important structural distinction between the two commonly referenced forms of CJC-1295.
| Feature | CJC-1295 (DAC) | CJC-1295 Without DAC |
|---|---|---|
| GHRH-derived | Yes | Yes |
| DAC modification | Present | Absent |
| Albumin-binding modification | Present | Absent |
| Circulating persistence | Extended through albumin association | Shorter experimental persistence |
| Research focus | Long-acting GHRH analogue and albumin binding | GHRH receptor and short-acting analogue research |
The two materials should therefore not be treated as interchangeable compounds. PubChem lists separate chemical records for CJC-1295 and CJC-1295 without DAC.
CJC-1295 (DAC) is supplied as a lyophilized research material with ≥99% HPLC-certified purity.
A Certificate of Analysis (COA) is included with the product documentation. Researchers should review the applicable batch documentation when evaluating identity, purity, and other reported analytical characteristics.
Quantity: 2 mg
Form: Lyophilized powder
Appearance: White to off-white
Purity: ≥99% HPLC Certified
Solubility: Soluble in laboratory-grade sterile water
COA: Included in product documentation
Intended Use: Laboratory research only
DAC refers to the Drug Affinity Complex, the structural modification that enables CJC-1295 to form a covalent association with albumin. This albumin interaction is responsible for the compound's extended circulation characteristics.
Growth hormone-releasing hormone (GHRH) is a hypothalamic peptide that regulates growth hormone secretion through interaction with the GHRH receptor on anterior pituitary cells.
The DAC modification contains a reactive maleimide group that can form a covalent bond with a cysteine residue on circulating albumin. This creates an albumin-associated form of the peptide with longer circulation than the unmodified GHRH analogue.
No. Both are GHRH-derived research compounds, but the DAC form contains the albumin-binding modification. CJC-1295 without DAC lacks this modification and therefore has different chemical and pharmacokinetic characteristics.
PubChem lists the molecular weight of CJC-1295 as approximately 3647.2 g/mol. The precise molecular mass can vary depending on the chemical form or salt state being evaluated.
Yes. Published research has evaluated CJC-1295 in healthy adult participants, including pharmacokinetic and endocrine-response measurements. These studies are separate from the laboratory research material described on this product page.
Review the CJC-1295 (DAC) scientific specifications and applicable Certificate of Analysis when evaluating this material for laboratory research. CJC-1295 (DAC) is supplied strictly as a research material and is not intended for human or veterinary use.
